This provides a possible mechanism of how virus infection causes hypersensitisation in the airways and indicates that TRPV1, TRPA1 and ASIC3, or upstream events leading to their activation, are potential therapeutic targets for the treatment of virus-induced cough. This evidence concerns the gene TRPV1 and Cough.